预约演示
更新于：2026-08-24
Drospirenone/Estradiol
雌二醇屈螺酮
更新于：2026-08-24
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H54O5 |
InChIKeyQJUXBIVLOGRZSQ-OQMMLGNJSA-N |
CAS号350818-73-4 |
关联
12
项与 雌二醇屈螺酮 相关的临床试验NCT03126773
A Prospective Multicenter Non-interventional Cohort Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
NCT02269241
A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
NCT01109979
Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study
100 项与 雌二醇屈螺酮 相关的临床结果
登录后查看更多信息
100 项与 雌二醇屈螺酮 相关的转化医学
登录后查看更多信息
100 项与 雌二醇屈螺酮 相关的专利（医药）
登录后查看更多信息
33
项与 雌二醇屈螺酮 相关的文献（医药）2018-01-01Kardiologiia4区 · 医学
Structural and functional changes of blood vessels in women in early postmenopause, the possibility of correction of the revealed violations
4区 · 医学
Article
作者: Rebrov, A P ; Salov, I A ; Tolstov, S N
AIM:
To evaluate severity and pattern of structural and functional changes of vascular wall in early postmenopausal women receiving chronic treatment with a low-dose combination of 17β-estradiol (E2) 1 mg and drospirenone 2 mg (DRSP). Evaluation of structural and functional arterial remodeling might be important for assessment of cardiovascular risk in postmenopausal women.
MATERIALS AND METHODS:
The study included 162 early postmenopausal women with postmenopausal syndrome. The women were divided into two groups. The main group consisted of 84 patients receiving the postmenopausal hormonal therapy (PMHT) with E2 1 mg / DRSP 2 mg (Angeliq, Bayer) and the control group included 78 women not receiving PMHT. The follow-up duration was 5.2 years. 24‑h blood pressure monitoring with evaluation of arterial stiffness (RWTT, AIx, ASI, AASI, (dP/dt) max) was performed. Endothelium-dependent dilation of the brachial artery was measured using the reactive hyperemia test. Aortic pulse wave velocity (aPWV) and common carotid intima-media thickness (ccIMT) were measured ultrasonically.
RESULTS:
At baseline, increased aPWV was observed in 15 (21.4 %) women of the main group and 19 (24.3 %) women of the control group (р=0.4). At the end of study, increased aPWV was observed in both groups but the increase was more pronounced in the control group. Increased pulse blood pressure (PBP) was observed in 27 (32.1 %) patients of the main group and 26 (33.3 %) patients of the control group (р=0.87). At the end of study, PBP decreased from 47.2±7.2 to 45.3±6.9 mm Hg (р.
2015-06-16Zhonghua yi xue za zhi
[Clinical and metabolic effects of drospirenone-estradiol versus tibolone in postmenopausal women:a comparative study].
Article
作者: Cheng, Jiao ; Zhang, Zhenyu
OBJECTIVE:
To compare the clinical and metabolic effects of drospirenone-estradiol (Angeliq) versus tibolone (Livial) in postmenopausal women.
METHODS:
Twenty-seven postmenopausal women of group 1 took Angeliq (1 dose every two days) while another group 2 (n = 26) received tibolone (2.5 mg every two days) as hormone replacement therapy for 12 weeks. A retrospective analysis was used to evaluate the clinical efficacy, safety and risk factors of cardiovascular metabolism. The clinical data were collected before and after treatment, including personal interview, medical examination and ultrasound imaging of pelvic, breast and carotid artery.
RESULTS:
No statistically significant inter-group differences existed in age or body mass index. Before treatment, the level of E2 was (12 ± 10) ng/L, triglyceride (TG) (2.0 ± 1.1) mmol/L, lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L, (1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2. After 12-week treatment, (30 ± 18) ng/L, (1.6 ± 1.1) mmol/L and (37 ± 36) mmol/L in group 1 versus (23 ± 9) ng/L, (1.1 ± 0.6) mmol/L and (18 ± 12) mmol/L in group 2. A greater incidence of vaginal bleeding and thicker endometrium were found in group 1.
CONCLUSION:
Angeliq can relieve menopausal symptoms. And its functions of regulating lipid metabolism and protecting cardiovascular system are better than those of Livial. However, its wider acceptability is limited by vaginal bleeding, thicker endometrium and breast pain.
2014-07-01Hospital pharmacy
New Connectors Coming for Enteral Feeding Tubes; Marqibo and Risk of Errors; Angeliq is Not a Birth Control Pill
Article
作者: Cohen, Michael R. ; Smetzer, Judy L.
These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program. Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below. Errors, close calls, or hazardous conditions may be reported directly to ISMP through the ISMP Web site ( www.ismp.org ), by calling 800-FAIL-SAFE, or via e-mail at ismpinfo@ismp.org . ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.
2
项与 雌二醇屈螺酮 相关的新闻（医药）2026-02-22
临床申请上市批准
2026-01-30
100 项与 雌二醇屈螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 更年期综合症 | 中国 | 2015-01-11 | |
| 绝经期后骨质疏松 | 中国 | 2009-09-29 | |
| 血管疾病 | 中国 | 2009-09-29 | |
| 血管舒缩症 | 美国 | 2005-09-28 | |
| 血管舒缩症 | 美国 | 2005-09-28 | |
| 外阴和阴道萎缩 | 美国 | 2005-09-28 | |
| 外阴和阴道萎缩 | 美国 | 2005-09-28 | |
| 避孕 | 加拿大 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,552 | 膚憲簾廠齋憲選襯餘積 = 衊鑰壓壓窪襯淵淵選餘 糧製餘構艱構壓壓餘簾 (鏇膚觸鑰蓋壓淵膚網糧, 夢衊簾膚憲醖艱糧遞觸 ~ 顧遞構鬱製範願簾鑰鏇) 更多 | - | 2019-07-23 | |||
临床4期 | 24 | 選蓋範膚蓋鏇繭淵夢製(網餘鬱鬱淵鬱選淵齋遞) = 簾構積憲築築蓋蓋壓鹹 範製選製觸積餘窪簾鹹 (築憲鑰簾窪繭觸鑰積獵, 3.32) 更多 | - | 2013-05-03 | |||
Drospirenone (DRSP)+Estradiol (E) (E+DRSP) | 選蓋範膚蓋鏇繭淵夢製(網餘鬱鬱淵鬱選淵齋遞) = 顧鏇築襯餘壓鑰鏇糧醖 範製選製觸積餘窪簾鹹 (築憲鑰簾窪繭觸鑰積獵, 3.18) 更多 | ||||||
临床2期 | 92 | (0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)) | 獵遞齋網鹹製範獵窪憲(廠衊鬱襯築遞夢鏇簾醖) = 鬱鏇網構鬱艱願鑰齋壓 壓鏇願齋醖鬱構醖壓憲 (製廠醖廠獵窪廠繭醖淵, 1.49) 更多 | - | 2010-01-20 | ||
(2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)) | 獵遞齋網鹹製範獵窪憲(廠衊鬱襯築遞夢鏇簾醖) = 構憲膚憲鏇襯膚艱築糧 壓鏇願齋醖鬱構醖壓憲 (製廠醖廠獵窪廠繭醖淵, 1.35) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用